Carregant...
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL). Despite significant efficacy in most CLL patients, some patients develop resistance to these agents and progress on these...
Guardat en:
| Publicat a: | Front Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330112/ https://ncbi.nlm.nih.gov/pubmed/32670873 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00894 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|